Angela Merkel

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023
First grade, Research, HS, AD, PD, Food, Safety, Dana–Farber Cancer Institute, Disease, Abstract, Immunology, Cutaneous T-cell lymphoma, Uveal melanoma, STAT3, International, Physician, GDF15, Webcast, Atopic dermatitis, Therapy, Investment, CTCL, Patient, Administration, Cash, Plasma, Lymphoma, Conference, IRAK4, Development, TPD, ASH, Growth, DL2, Hypotension, DL, Solar cycle 4, Arm, AACR, Thrombocytopenia, Fast Track, PTCL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Society, SD, Hidradenitis suppurativa, MDM2, Recurrence, Blood, Peripheral T-cell lymphoma, Neutropenia, AML, Merkel-cell carcinoma, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Angela Merkel, Sanofi, Black Majesty

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, FDA, Standard of care, SOC, Angela Merkel, Food, Fast track (FDA), NEAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MCC, LAMP, ITI, FIH, Clinical trial, Recurrence, Merkel cell polyomavirus, Safety, Plasmid, Therapy, Patient, Skin cancer, FTD, DNA, Merkel-cell carcinoma, Pharmaceutical industry

ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.

Key Points: 
  • ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.
  • As we are encouraged by the immunological responses in patients, we look forward to continuing the development of ITI-3000.
  • The phase 1 clinical trial was a six-patient, single center, open label, first-in-human (FIH) study, investigating the safety, tolerability and immunogenicity of ITI-3000 in patients with polyomavirus-positive Merkel cell carcinoma (MCC).
  • Additional information regarding the phase 1 trial may be found at clinicaltrials.gov , using identifier: NCT05422781.

EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Annual general meeting, Cancer, Health care, Food, UC, MCC, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, Merck, LA, Neck, Maintenance, Bladder cancer, Merck Group, Lung, Head, Merck Serono, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.
  • In September 2023, the accelerated approval in the US was converted into full approval for use of BAVENCIO for the treatment of metastatic MCC.

Merck to Present Latest Research from Oncology Portfolio at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Annual general meeting, Cancer, Cetuximab, UC, Food, MCC, Biomarker, Abstract, IAP, NSCLC, Apoptosis, European Society for Medical Oncology, Cisplatin, OS, Ageing, Safety, Lung cancer, US Foods, Angela Merkel, Patient, FDA, ESMO, Chemoradiotherapy, Skin cancer, Phase, Booth, LA, Neck, Maintenance, Bladder cancer, Lung, Head, Avelumab, Progression-free survival, MET, SCCHN, Pharmaceutical industry, Nightclub, Merck

Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.

Key Points: 
  • Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting, October 20-24, Madrid, Spain.
  • Presentations at the meeting encompass new analyses for the standard-of-care medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab).
  • Additional presentations and activities at ESMO highlight the company’s efforts to improve the lives of people with cancer.
  • New analyses and real-world evidence to be presented at ESMO reinforce the role of the JAVELIN Bladder regimen in this setting.

pgEdge Platform, the First Fully Distributed Edge Database Based on Standard PostgreSQL, is Now Generally Available

Retrieved on: 
Thursday, October 12, 2023
Cloud, PostgreSQL, Azure, Microsoft, AWS, Machine learning, OS, Table, GA, Database, Google Cloud Platform, PostGIS, PL/pgSQL, ACE, Video game, Security printing, Cryptocurrency, Angela Merkel

ALEXANDRIA, Va., Oct. 12, 2023 /PRNewswire/ -- pgEdge, Inc. announced general availability of pgEdge Platform, the first fully open and fully distributed PostgreSQL database designed to run at or near the network edge and between cloud regions. With this milestone release – and after a seven-month beta period – pgEdge will now provide support for customers moving applications deployed on pgEdge Platform into production.

Key Points: 
  • For application developers and database architects looking to deploy low latency and/or high availability applications that need to be globally distributed, pgEdge Distributed PostgreSQL is a multi-master (active-active) distributed database system.
  • New enhancements and features include:
    Anti-Chaos Engine: The pgEdge Anti-Chaos Engine (ACE) ensures consistency between database nodes in a pgEdge distributed cluster.
  • "We are excited to announce that pgEdge Platform is now generally available," said Phillip Merrick, Co-founder and CEO of pgEdge.
  • pgEdge Cloud, a fully managed cloud service based on pgEdge Platform, will be generally available within a few months.

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Retrieved on: 
Thursday, June 29, 2023
Survival rate, STAT3, University, Glomus tumor, Bromodeoxyuridine, Merkel cell polyomavirus, Necrosis, Journal of Cancer Research and Clinical Oncology, Skin cancer, Quality of life, Ruhr University Bochum, University of Duisburg-Essen, AKT, Patient, Manuscript, Cancer, Flow cytometry, MCC, Apoptosis, MTT, Organ (biology), ST, Pharmaceutical industry, Vaccine, Panaveli, Angela Merkel, Erosion (morphology)

BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced the publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel cell carcinoma cells: preliminary results1,” in the peer-reviewed Journal of Cancer Research and Clinical Oncology.

Key Points: 
  • The objective of the preclinical study was to investigate the effects of GP-2250 on Merkel cell polyomavirus (MCPyV)-negative MCC cells.
  • Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer.
  • This study was able to show that GP-2250 has significant, dose-dependent cytotoxic effects on MCC cells as well as reduced cancer cell proliferation and migration.
  • GP-2250’s effects on cell viability, proliferation and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively.

Gate.io Launches Shark Fin Boost on Gate Wealth, Offering Principal-Protected Investment Product with High APR

Retrieved on: 
Monday, June 5, 2023
BTC, USDT, Investment, Safety, ETH, Multimedia, Cryptocurrency, Online shopping, Angela Merkel

MAJURO, Marshall Islands, June 5, 2023 /PRNewswire/ -- Gate.io, a leading cryptocurrency exchange, is launching Shark Fin Boost and Shark Fin Wealth, two new principal-protected investment products with an APR of up to 14%.

Key Points: 
  • MAJURO, Marshall Islands, June 5, 2023 /PRNewswire/ -- Gate.io, a leading cryptocurrency exchange, is launching Shark Fin Boost and Shark Fin Wealth, two new principal-protected investment products with an APR of up to 14%.
  • Shark Fin Boost provides a guaranteed return of at least 7% but can go as high as 14% and features no minimum investment requirement.
  • Based on past similar investment product launches, Boost and Wealth are anticipated to reach full subscription within one hour after launch.
  • Shark Fin Boost and Wealth are part of a suite of structured investment products offered on the Gate Wealth platform.

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Retrieved on: 
Monday, June 5, 2023
ICIS, ICI, Merkel-cell carcinoma, Cancer, ASCO, American Society of Clinical Oncology, Patient, Annual general meeting, MCC, Research institute, Squamous-cell carcinoma, Pembrolizumab, Society, ClinicalTrials.gov, Safety, Pharmaceutical industry, Vaccine, Angela Merkel, FA, Morphogenesis, MD

TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome primary and acquired resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.

Key Points: 
  • “While patients with advanced Merkel cell carcinoma and cutaneous Squamous cell carcinoma exhibit high response rates to immune checkpoint inhibitor therapy, the approximately 50% of patients who fail to respond have limited treatment options.
  • In a Phase 1 study in advanced melanoma, biomarker analyses demonstrated robust immune priming effects of IFx administration.
  • For more information about the company’s ongoing Phase 1b IFx-Hu2.0 study, visit Clinicaltrials.gov and reference Identifier NCT04160065 .
  • The combined company is expected to operate under the name “TuHURA Biosciences, Inc.” and to trade on The Nasdaq Capital Market (“Nasdaq”).

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Tuesday, May 30, 2023
Morphogenesis, Merkel-cell carcinoma, Cancer, ASCO, American Society of Clinical Oncology, Annual general meeting, Society, Pharmaceutical industry, Angela Merkel

TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.

Key Points: 
  • TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
  • The combined company will focus on advancing Morphogenesis’ two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
  • The combined company is expected to operate under the name “TuHURA Biosciences, Inc.” and to trade on The Nasdaq Capital Market (“Nasdaq”).
  • The transaction is expected to close in the third quarter of 2023.

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

Retrieved on: 
Friday, April 14, 2023
Health, Clinical Trials, General Health, Research, Pharmaceutical, Science, Myelocyte, AACR, PD, LILRB2, LILRB4, CD3, ILT3, Merkel-cell carcinoma, Pharmacokinetics, American Association for Cancer Research, Biomarker, Immunotherapy, ILT4, Patient, Pembrolizumab, Therapy, Disease, Safety, Tislelizumab, Vaccine, Pharmaceutical industry, Angela Merkel

The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.

Key Points: 
  • The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.
  • Preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will also be presented on April 18 as a late-breaking poster at AACR 2023.
  • Treatment with IO-108 was well-tolerated to the maximum administered dose (1800 mg Q3W); the maximum tolerated dose was not reached.
  • These findings suggest that LILRB2 is a critically important immunotherapy target.”
    The initial data from dose escalation supports further development of IO-108.